← 產業報告目錄
Orphan Drugs CDMO Market Size, Share & Trends Analysis Report By Drug Type (Biologics, Non-biologics), By Therapy Type (Oncology, Neuromuscular, Respiratory, Hematology, Others), By End-User (Pharmaceutical companies, Biotechnology companies, CROs, Other End Users), By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-20頁數 179報告編號 INSIGHTACE-8b978ffe97
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Orphan Drugs CDMO Market on a global scale was estimated at USD 13.5 Bn in 2024 and is forecasted to attain USD 27.6 Bn by 2034, with a projected CAGR of 7.5% between 2025 and 2034.
The Orphan Drugs CDMO sector involves pharmaceuticals designed to treat rare medical illnesses known as orphan diseases. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is fueled by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Orphan Drugs CDMO Market Snapshot
Chapter 4. Global Orphan Drugs CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Type Estimates & Trend Analysis
5.1. By Drug Type, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Type:
5.2.1. Biologics
5.2.2. Non-biologics
Chapter 6. Market Segmentation 2: By Therapy Type Estimates & Trend Analysis
6.1. By Therapy Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapy Type:
6.2.1. Oncology
6.2.2. Neuromuscular
6.2.3. Respiratory
6.2.4. Hematology
6.2.5. Others
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. By End User & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End User:
7.2.1. Pharmaceutical companies
7.2.2. Biotechnology companies
7.2.3. CROs
7.2.4. Other End Users
Chapter 8. Orphan Drugs CDMO Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034
8.1.2. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts By Therapy Type, 2021-2034
8.1.3. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
8.1.4. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, 2021-2034
8.2.2. Europe Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, 2021-2034
8.2.3. Europe Orphan Drugs CDMO Market revenue (US$ Million) By End User, 2021-2034
8.2.4. Europe Orphan Drugs CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, 2021-2034
8.3.2. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, 2021-2034
8.3.3. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) By End User, 2021-2034
8.3.4. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, (US$ Million) 2021-2034
8.4.2. Latin America Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, (US$ Million) 2021-2034
8.4.3. Latin America Orphan Drugs CDMO Market revenue (US$ Million) By End User, (US$ Million) 2021-2034
8.4.4. Latin America Orphan Drugs CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) By End User, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Novartis AG
9.2.2. F. Hoffmann-La Roche Ltd
9.2.3. Celgene, Bristol-Myers Squibb Company
9.2.4. Sanofi
9.2.5. Bayer Healthcare
9.2.6. Doppel
9.2.7. Lubrizol Life Science (LLS) Health
9.2.8. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們